nodes	percent_of_prediction	percent_of_DWPC	metapath
Rifabutin—CYP3A4—bone cancer	0.756	1	CbGaD
Rifabutin—Burkitt's lymphoma—Methotrexate—bone cancer	0.0132	0.186	CcSEcCtD
Rifabutin—HSP90B1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00967	0.061	CbGpPWpGaD
Rifabutin—HSP90AA1—LKB1 signaling events—ETV4—bone cancer	0.009	0.0567	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00886	0.0558	CbGpPWpGaD
Rifabutin—Rifaximin—NR1I2—bone cancer	0.00814	0.574	CrCbGaD
Rifabutin—HSP90AA1—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—DHFR—bone cancer	0.00686	0.0432	CbGpPWpGaD
Rifabutin—HSP90B1—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.00672	0.0423	CbGpPWpGaD
Rifabutin—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00513	0.0323	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism of nitric oxide—DHFR—bone cancer	0.00475	0.0299	CbGpPWpGaD
Rifabutin—HSP90B1—Unfolded Protein Response (UPR)—EIF2S1—bone cancer	0.00421	0.0265	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.00419	0.0264	CbGpPWpGaD
Rifabutin—HSP90AA1—Loss of Nlp from mitotic centrosomes—TUBB4B—bone cancer	0.00332	0.0209	CbGpPWpGaD
Rifabutin—HSP90AA1—Centrosome maturation—TUBB4B—bone cancer	0.00294	0.0185	CbGpPWpGaD
Rifabutin—Rifampicin—NR1I2—bone cancer	0.00292	0.206	CrCbGaD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—BMI1—bone cancer	0.00291	0.0183	CbGpPWpGaD
Rifabutin—HSP90AA1—Regulation of PLK1 Activity at G2/M Transition—TUBB4B—bone cancer	0.0027	0.017	CbGpPWpGaD
Rifabutin—HSP90AA1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00265	0.0167	CbGpPWpGaD
Rifabutin—HSP90AA1—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.00262	0.0165	CbGpPWpGaD
Rifabutin—HSP90B1—Metabolism of proteins—MOGS—bone cancer	0.00225	0.0142	CbGpPWpGaD
Rifabutin—HSP90B1—Toll-Like Receptors Cascades—ATF1—bone cancer	0.00213	0.0134	CbGpPWpGaD
Rifabutin—HSP90AA1—Regulation of Telomerase—WT1—bone cancer	0.00206	0.013	CbGpPWpGaD
Rifabutin—HSP90AA1—G2/M Transition—TUBB4B—bone cancer	0.00203	0.0128	CbGpPWpGaD
Rifabutin—HSP90AA1—Mitotic G2-G2/M phases—TUBB4B—bone cancer	0.002	0.0126	CbGpPWpGaD
Rifabutin—HSP90B1—IL6-mediated signaling events—JUN—bone cancer	0.00199	0.0126	CbGpPWpGaD
Rifabutin—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00188	0.0119	CbGpPWpGaD
Rifabutin—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00168	0.0106	CbGpPWpGaD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—EIF2S1—bone cancer	0.00163	0.0103	CbGpPWpGaD
Rifabutin—Rifaximin—CYP3A4—bone cancer	0.00161	0.114	CrCbGaD
Rifabutin—HSP90AA1—ErbB receptor signaling network—EGFR—bone cancer	0.00153	0.00962	CbGpPWpGaD
Rifabutin—Bacterial infection—Methotrexate—bone cancer	0.00137	0.0193	CcSEcCtD
Rifabutin—HSP90AA1—Integrins in angiogenesis—TGFBR2—bone cancer	0.00132	0.00831	CbGpPWpGaD
Rifabutin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0013	0.00819	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by constitutively active EGFR—EGFR—bone cancer	0.00126	0.00797	CbGpPWpGaD
Rifabutin—HSP90AA1—Corticotropin-releasing hormone—GNA11—bone cancer	0.00126	0.00792	CbGpPWpGaD
Rifabutin—HSP90AA1—Integrins in angiogenesis—IGF1R—bone cancer	0.00124	0.00782	CbGpPWpGaD
Rifabutin—HSP90B1—Metabolism of proteins—TUBB4B—bone cancer	0.00123	0.00777	CbGpPWpGaD
Rifabutin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00122	0.0077	CbGpPWpGaD
Rifabutin—Myositis—Epirubicin—bone cancer	0.00121	0.017	CcSEcCtD
Rifabutin—Pain—Carboplatin—bone cancer	0.0012	0.0169	CcSEcCtD
Rifabutin—Lymphopenia—Epirubicin—bone cancer	0.00116	0.0163	CcSEcCtD
Rifabutin—Myositis—Doxorubicin—bone cancer	0.00112	0.0157	CcSEcCtD
Rifabutin—Body temperature increased—Carboplatin—bone cancer	0.00111	0.0156	CcSEcCtD
Rifabutin—HSP90AA1—Cellular responses to stress—BMI1—bone cancer	0.00111	0.00698	CbGpPWpGaD
Rifabutin—Lymphopenia—Doxorubicin—bone cancer	0.00107	0.015	CcSEcCtD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00107	0.00674	CbGpPWpGaD
Rifabutin—HSP90B1—Metabolism of proteins—TUBB2A—bone cancer	0.00106	0.0067	CbGpPWpGaD
Rifabutin—HSP90AA1—Hypoxic and oxygen homeostasis regulation of HIF-1-alpha—TP53—bone cancer	0.00106	0.00669	CbGpPWpGaD
Rifabutin—Aphasia—Methotrexate—bone cancer	0.000974	0.0137	CcSEcCtD
Rifabutin—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000971	0.00612	CbGpPWpGaD
Rifabutin—Rifapentine—CYP3A4—bone cancer	0.000926	0.0653	CrCbGaD
Rifabutin—HSP90AA1—Semaphorin interactions—MET—bone cancer	0.00091	0.00574	CbGpPWpGaD
Rifabutin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000909	0.00573	CbGpPWpGaD
Rifabutin—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000884	0.00557	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000879	0.00554	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—ZW10—bone cancer	0.000852	0.00537	CbGpPWpGaD
Rifabutin—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000846	0.00533	CbGpPWpGaD
Rifabutin—HSP90B1—Toll-Like Receptors Cascades—JUN—bone cancer	0.000828	0.00522	CbGpPWpGaD
Rifabutin—HSP90AA1—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000814	0.00513	CbGpPWpGaD
Rifabutin—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000812	0.00512	CbGpPWpGaD
Rifabutin—HSP90AA1—Integrin-linked kinase signaling—JUN—bone cancer	0.000806	0.00508	CbGpPWpGaD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.000798	0.00503	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—bone cancer	0.000796	0.00502	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000792	0.00499	CbGpPWpGaD
Rifabutin—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000781	0.00492	CbGpPWpGaD
Rifabutin—HSP90B1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000764	0.00482	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—ZW10—bone cancer	0.000762	0.0048	CbGpPWpGaD
Rifabutin—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000753	0.0106	CcSEcCtD
Rifabutin—HSP90B1—Metabolism of proteins—EIF2S1—bone cancer	0.000742	0.00468	CbGpPWpGaD
Rifabutin—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000724	0.00457	CbGpPWpGaD
Rifabutin—HSP90AA1—Regulation of Androgen receptor activity—JUN—bone cancer	0.000707	0.00446	CbGpPWpGaD
Rifabutin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000702	0.00442	CbGpPWpGaD
Rifabutin—Skin discolouration—Methotrexate—bone cancer	0.0007	0.00984	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—ATF1—bone cancer	0.000689	0.00434	CbGpPWpGaD
Rifabutin—Pancytopenia—Cisplatin—bone cancer	0.000686	0.00965	CcSEcCtD
Rifabutin—HSP90AA1—NRF2 pathway—TGFBR2—bone cancer	0.000673	0.00424	CbGpPWpGaD
Rifabutin—HSP90AA1—NRF2 pathway—GSTP1—bone cancer	0.000673	0.00424	CbGpPWpGaD
Rifabutin—Hepatic enzyme increased—Methotrexate—bone cancer	0.000668	0.0094	CcSEcCtD
Rifabutin—Skin discolouration—Epirubicin—bone cancer	0.000655	0.00921	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000646	0.00407	CbGpPWpGaD
Rifabutin—Blood bilirubin increased—Epirubicin—bone cancer	0.000625	0.0088	CcSEcCtD
Rifabutin—HSP90AA1—Corticotropin-releasing hormone—BRAF—bone cancer	0.000625	0.00394	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000623	0.00393	CbGpPWpGaD
Rifabutin—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000623	0.00393	CbGpPWpGaD
Rifabutin—Hepatobiliary disease—Cisplatin—bone cancer	0.000609	0.00857	CcSEcCtD
Rifabutin—Skin discolouration—Doxorubicin—bone cancer	0.000606	0.00852	CcSEcCtD
Rifabutin—Phosphatase alkaline increased—Epirubicin—bone cancer	0.000591	0.00832	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—RFC1—bone cancer	0.000585	0.00369	CbGpPWpGaD
Rifabutin—Eructation—Epirubicin—bone cancer	0.000581	0.00817	CcSEcCtD
Rifabutin—HSP90AA1—Regulation of Telomerase—JUN—bone cancer	0.00058	0.00365	CbGpPWpGaD
Rifabutin—HSP90AA1—EPH-Ephrin signaling—MMP2—bone cancer	0.000579	0.00365	CbGpPWpGaD
Rifabutin—Blood bilirubin increased—Doxorubicin—bone cancer	0.000579	0.00814	CcSEcCtD
Rifabutin—Rifampicin—CYP3A4—bone cancer	0.000578	0.0408	CrCbGaD
Rifabutin—HSP90AA1—Cell Cycle—TUBB4B—bone cancer	0.000577	0.00364	CbGpPWpGaD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	0.000574	0.00362	CbGpPWpGaD
Rifabutin—Connective tissue disorder—Cisplatin—bone cancer	0.000568	0.008	CcSEcCtD
Rifabutin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000559	0.00352	CbGpPWpGaD
Rifabutin—HSP90AA1—LKB1 signaling events—TP53—bone cancer	0.000552	0.00348	CbGpPWpGaD
Rifabutin—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000547	0.0077	CcSEcCtD
Rifabutin—Eye disorder—Cisplatin—bone cancer	0.000541	0.0076	CcSEcCtD
Rifabutin—HSP90AA1—Cellular responses to stress—EZH2—bone cancer	0.000538	0.00339	CbGpPWpGaD
Rifabutin—Eructation—Doxorubicin—bone cancer	0.000538	0.00756	CcSEcCtD
Rifabutin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000531	0.00335	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—RFC1—bone cancer	0.000523	0.0033	CbGpPWpGaD
Rifabutin—Immune system disorder—Cisplatin—bone cancer	0.000522	0.00735	CcSEcCtD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.0005	0.00315	CbGpPWpGaD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—JUN—bone cancer	0.000499	0.00314	CbGpPWpGaD
Rifabutin—Flatulence—Cisplatin—bone cancer	0.000496	0.00698	CcSEcCtD
Rifabutin—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000494	0.00694	CcSEcCtD
Rifabutin—Anaemia—Cisplatin—bone cancer	0.000465	0.00655	CcSEcCtD
Rifabutin—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000458	0.00289	CbGpPWpGaD
Rifabutin—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000457	0.00642	CcSEcCtD
Rifabutin—HSP90AA1—Regulation of Telomerase—EGFR—bone cancer	0.000456	0.00287	CbGpPWpGaD
Rifabutin—HSP90AA1—TNF alpha Signaling Pathway—JUN—bone cancer	0.000455	0.00287	CbGpPWpGaD
Rifabutin—Leukopenia—Cisplatin—bone cancer	0.000451	0.00634	CcSEcCtD
Rifabutin—Convulsion—Cisplatin—bone cancer	0.000436	0.00614	CcSEcCtD
Rifabutin—HSP90AA1—EPH-Ephrin signaling—MMP9—bone cancer	0.000435	0.00274	CbGpPWpGaD
Rifabutin—Myalgia—Cisplatin—bone cancer	0.000429	0.00603	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000426	0.00599	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by ERBB2—KIT—bone cancer	0.000421	0.00265	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—GSTP1—bone cancer	0.000419	0.00264	CbGpPWpGaD
Rifabutin—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000417	0.00263	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—NDUFA12—bone cancer	0.000414	0.00261	CbGpPWpGaD
Rifabutin—Thrombocytopenia—Cisplatin—bone cancer	0.000402	0.00566	CcSEcCtD
Rifabutin—HSP90B1—Immune System—ATF1—bone cancer	0.000401	0.00253	CbGpPWpGaD
Rifabutin—Skin disorder—Cisplatin—bone cancer	0.000399	0.00561	CcSEcCtD
Rifabutin—Eosinophilia—Methotrexate—bone cancer	0.000393	0.00552	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—KIT—bone cancer	0.000392	0.00247	CbGpPWpGaD
Rifabutin—Anorexia—Cisplatin—bone cancer	0.000392	0.00551	CcSEcCtD
Rifabutin—HSP90B1—Immune System—IL3—bone cancer	0.000391	0.00247	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—KIT—bone cancer	0.000387	0.00244	CbGpPWpGaD
Rifabutin—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000387	0.00544	CcSEcCtD
Rifabutin—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000379	0.00533	CcSEcCtD
Rifabutin—Pancytopenia—Methotrexate—bone cancer	0.000377	0.0053	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000374	0.00527	CcSEcCtD
Rifabutin—Neutropenia—Methotrexate—bone cancer	0.000371	0.00522	CcSEcCtD
Rifabutin—Paraesthesia—Cisplatin—bone cancer	0.000369	0.00519	CcSEcCtD
Rifabutin—Eosinophilia—Epirubicin—bone cancer	0.000367	0.00517	CcSEcCtD
Rifabutin—Dyspnoea—Cisplatin—bone cancer	0.000366	0.00515	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—DHFR—bone cancer	0.000363	0.00229	CbGpPWpGaD
Rifabutin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000358	0.00503	CcSEcCtD
Rifabutin—Decreased appetite—Cisplatin—bone cancer	0.000357	0.00502	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Cisplatin—bone cancer	0.000355	0.00499	CcSEcCtD
Rifabutin—Pancytopenia—Epirubicin—bone cancer	0.000352	0.00496	CcSEcCtD
Rifabutin—Pain—Cisplatin—bone cancer	0.000351	0.00494	CcSEcCtD
Rifabutin—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.00035	0.00493	CcSEcCtD
Rifabutin—Neutropenia—Epirubicin—bone cancer	0.000347	0.00488	CcSEcCtD
Rifabutin—HSP90AA1—Metabolism—NT5C3A—bone cancer	0.000343	0.00216	CbGpPWpGaD
Rifabutin—Eosinophilia—Doxorubicin—bone cancer	0.00034	0.00478	CcSEcCtD
Rifabutin—HSP90AA1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.000339	0.00214	CbGpPWpGaD
Rifabutin—Feeling abnormal—Cisplatin—bone cancer	0.000339	0.00476	CcSEcCtD
Rifabutin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000337	0.00213	CbGpPWpGaD
Rifabutin—Hepatobiliary disease—Methotrexate—bone cancer	0.000334	0.0047	CcSEcCtD
Rifabutin—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000333	0.0021	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by ERBB2—MDM2—bone cancer	0.000331	0.00209	CbGpPWpGaD
Rifabutin—Agranulocytosis—Methotrexate—bone cancer	0.00033	0.00464	CcSEcCtD
Rifabutin—HSP90AA1—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000329	0.00208	CbGpPWpGaD
Rifabutin—Pancytopenia—Doxorubicin—bone cancer	0.000326	0.00459	CcSEcCtD
Rifabutin—Body temperature increased—Cisplatin—bone cancer	0.000325	0.00457	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle—DHFR—bone cancer	0.000324	0.00204	CbGpPWpGaD
Rifabutin—Jaundice—Epirubicin—bone cancer	0.000323	0.00454	CcSEcCtD
Rifabutin—Neutropenia—Doxorubicin—bone cancer	0.000321	0.00452	CcSEcCtD
Rifabutin—Hepatitis—Methotrexate—bone cancer	0.000317	0.00446	CcSEcCtD
Rifabutin—Hepatobiliary disease—Epirubicin—bone cancer	0.000313	0.0044	CcSEcCtD
Rifabutin—Agranulocytosis—Epirubicin—bone cancer	0.000309	0.00434	CcSEcCtD
Rifabutin—HSP90B1—Innate Immune System—MDM2—bone cancer	0.000309	0.00195	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—MDM2—bone cancer	0.000305	0.00192	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—CDK4—bone cancer	0.000304	0.00192	CbGpPWpGaD
Rifabutin—HSP90B1—Metabolism of proteins—MMP2—bone cancer	0.000303	0.00191	CbGpPWpGaD
Rifabutin—Hypersensitivity—Cisplatin—bone cancer	0.000303	0.00426	CcSEcCtD
Rifabutin—Jaundice—Doxorubicin—bone cancer	0.000298	0.0042	CcSEcCtD
Rifabutin—Hepatitis—Epirubicin—bone cancer	0.000297	0.00418	CcSEcCtD
Rifabutin—Eye disorder—Methotrexate—bone cancer	0.000297	0.00417	CcSEcCtD
Rifabutin—Asthenia—Cisplatin—bone cancer	0.000295	0.00415	CcSEcCtD
Rifabutin—Connective tissue disorder—Epirubicin—bone cancer	0.000292	0.00411	CcSEcCtD
Rifabutin—Hepatobiliary disease—Doxorubicin—bone cancer	0.00029	0.00407	CcSEcCtD
Rifabutin—Immune system disorder—Methotrexate—bone cancer	0.000287	0.00403	CcSEcCtD
Rifabutin—Agranulocytosis—Doxorubicin—bone cancer	0.000286	0.00402	CcSEcCtD
Rifabutin—Diarrhoea—Cisplatin—bone cancer	0.000281	0.00395	CcSEcCtD
Rifabutin—Eye disorder—Epirubicin—bone cancer	0.000278	0.0039	CcSEcCtD
Rifabutin—Hepatitis—Doxorubicin—bone cancer	0.000275	0.00387	CcSEcCtD
Rifabutin—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000273	0.00172	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—CHEK2—bone cancer	0.000271	0.00171	CbGpPWpGaD
Rifabutin—Dysgeusia—Methotrexate—bone cancer	0.000271	0.00381	CcSEcCtD
Rifabutin—Connective tissue disorder—Doxorubicin—bone cancer	0.00027	0.0038	CcSEcCtD
Rifabutin—HSP90AA1—Innate Immune System—ATF1—bone cancer	0.000269	0.00169	CbGpPWpGaD
Rifabutin—HSP90B1—Innate Immune System—JUN—bone cancer	0.000268	0.00169	CbGpPWpGaD
Rifabutin—Immune system disorder—Epirubicin—bone cancer	0.000268	0.00377	CcSEcCtD
Rifabutin—HSP90AA1—Cellular responses to stress—RB1—bone cancer	0.000264	0.00167	CbGpPWpGaD
Rifabutin—Vomiting—Cisplatin—bone cancer	0.000261	0.00368	CcSEcCtD
Rifabutin—Rash—Cisplatin—bone cancer	0.000259	0.00364	CcSEcCtD
Rifabutin—Dermatitis—Cisplatin—bone cancer	0.000259	0.00364	CcSEcCtD
Rifabutin—HSP90AA1—Axon guidance—MET—bone cancer	0.000258	0.00163	CbGpPWpGaD
Rifabutin—Eye disorder—Doxorubicin—bone cancer	0.000257	0.00361	CcSEcCtD
Rifabutin—Anaemia—Methotrexate—bone cancer	0.000255	0.00359	CcSEcCtD
Rifabutin—Flatulence—Epirubicin—bone cancer	0.000255	0.00358	CcSEcCtD
Rifabutin—Dysgeusia—Epirubicin—bone cancer	0.000253	0.00356	CcSEcCtD
Rifabutin—Immune system disorder—Doxorubicin—bone cancer	0.000248	0.00349	CcSEcCtD
Rifabutin—Leukopenia—Methotrexate—bone cancer	0.000247	0.00348	CcSEcCtD
Rifabutin—Nausea—Cisplatin—bone cancer	0.000244	0.00343	CcSEcCtD
Rifabutin—Convulsion—Methotrexate—bone cancer	0.000239	0.00337	CcSEcCtD
Rifabutin—Anaemia—Epirubicin—bone cancer	0.000239	0.00336	CcSEcCtD
Rifabutin—Flatulence—Doxorubicin—bone cancer	0.000236	0.00332	CcSEcCtD
Rifabutin—Arthralgia—Methotrexate—bone cancer	0.000235	0.00331	CcSEcCtD
Rifabutin—Chest pain—Methotrexate—bone cancer	0.000235	0.00331	CcSEcCtD
Rifabutin—Myalgia—Methotrexate—bone cancer	0.000235	0.00331	CcSEcCtD
Rifabutin—Dysgeusia—Doxorubicin—bone cancer	0.000234	0.0033	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000234	0.00329	CcSEcCtD
Rifabutin—Leukopenia—Epirubicin—bone cancer	0.000231	0.00326	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle—BRCA2—bone cancer	0.00023	0.00145	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—KIT—bone cancer	0.000228	0.00144	CbGpPWpGaD
Rifabutin—Confusional state—Methotrexate—bone cancer	0.000227	0.0032	CcSEcCtD
Rifabutin—HSP90AA1—Signaling by ERBB2—EGFR—bone cancer	0.000226	0.00143	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—MDM2—bone cancer	0.000225	0.00142	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000225	0.00142	CbGpPWpGaD
Rifabutin—Convulsion—Epirubicin—bone cancer	0.000224	0.00315	CcSEcCtD
Rifabutin—Anaemia—Doxorubicin—bone cancer	0.000221	0.00311	CcSEcCtD
Rifabutin—Thrombocytopenia—Methotrexate—bone cancer	0.000221	0.00311	CcSEcCtD
Rifabutin—Arthralgia—Epirubicin—bone cancer	0.00022	0.0031	CcSEcCtD
Rifabutin—Chest pain—Epirubicin—bone cancer	0.00022	0.0031	CcSEcCtD
Rifabutin—Myalgia—Epirubicin—bone cancer	0.00022	0.0031	CcSEcCtD
Rifabutin—Skin disorder—Methotrexate—bone cancer	0.000219	0.00308	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000219	0.00308	CcSEcCtD
Rifabutin—HSP90AA1—Axon guidance—MMP2—bone cancer	0.000215	0.00136	CbGpPWpGaD
Rifabutin—Anorexia—Methotrexate—bone cancer	0.000215	0.00302	CcSEcCtD
Rifabutin—Leukopenia—Doxorubicin—bone cancer	0.000214	0.00301	CcSEcCtD
Rifabutin—Confusional state—Epirubicin—bone cancer	0.000213	0.00299	CcSEcCtD
Rifabutin—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000212	0.00134	CbGpPWpGaD
Rifabutin—HSP90B1—Innate Immune System—EGFR—bone cancer	0.000211	0.00133	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling by EGFR in Cancer—EGFR—bone cancer	0.000208	0.00131	CbGpPWpGaD
Rifabutin—Shock—Epirubicin—bone cancer	0.000208	0.00292	CcSEcCtD
Rifabutin—Convulsion—Doxorubicin—bone cancer	0.000207	0.00292	CcSEcCtD
Rifabutin—Thrombocytopenia—Epirubicin—bone cancer	0.000207	0.00291	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000205	0.00289	CcSEcCtD
Rifabutin—Skin disorder—Epirubicin—bone cancer	0.000205	0.00288	CcSEcCtD
Rifabutin—Insomnia—Methotrexate—bone cancer	0.000204	0.00287	CcSEcCtD
Rifabutin—Chest pain—Doxorubicin—bone cancer	0.000204	0.00287	CcSEcCtD
Rifabutin—Arthralgia—Doxorubicin—bone cancer	0.000204	0.00287	CcSEcCtD
Rifabutin—Myalgia—Doxorubicin—bone cancer	0.000204	0.00287	CcSEcCtD
Rifabutin—Paraesthesia—Methotrexate—bone cancer	0.000202	0.00285	CcSEcCtD
Rifabutin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000202	0.00285	CcSEcCtD
Rifabutin—Anorexia—Epirubicin—bone cancer	0.000201	0.00283	CcSEcCtD
Rifabutin—Dyspnoea—Methotrexate—bone cancer	0.000201	0.00283	CcSEcCtD
Rifabutin—Dyspepsia—Methotrexate—bone cancer	0.000198	0.00279	CcSEcCtD
Rifabutin—Confusional state—Doxorubicin—bone cancer	0.000197	0.00277	CcSEcCtD
Rifabutin—Decreased appetite—Methotrexate—bone cancer	0.000196	0.00276	CcSEcCtD
Rifabutin—HSP90AA1—Cellular responses to stress—JUN—bone cancer	0.000196	0.00123	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—GRM4—bone cancer	0.000195	0.00123	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—RGS1—bone cancer	0.000195	0.00123	CbGpPWpGaD
Rifabutin—Gastrointestinal disorder—Methotrexate—bone cancer	0.000195	0.00274	CcSEcCtD
Rifabutin—Pain—Methotrexate—bone cancer	0.000193	0.00271	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000192	0.0027	CcSEcCtD
Rifabutin—Shock—Doxorubicin—bone cancer	0.000192	0.0027	CcSEcCtD
Rifabutin—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000192	0.00121	CbGpPWpGaD
Rifabutin—Thrombocytopenia—Doxorubicin—bone cancer	0.000191	0.00269	CcSEcCtD
Rifabutin—Insomnia—Epirubicin—bone cancer	0.000191	0.00268	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—CDK4—bone cancer	0.000191	0.0012	CbGpPWpGaD
Rifabutin—Skin disorder—Doxorubicin—bone cancer	0.00019	0.00267	CcSEcCtD
Rifabutin—Paraesthesia—Epirubicin—bone cancer	0.000189	0.00267	CcSEcCtD
Rifabutin—Dyspnoea—Epirubicin—bone cancer	0.000188	0.00265	CcSEcCtD
Rifabutin—Anorexia—Doxorubicin—bone cancer	0.000186	0.00262	CcSEcCtD
Rifabutin—Feeling abnormal—Methotrexate—bone cancer	0.000186	0.00261	CcSEcCtD
Rifabutin—Dyspepsia—Epirubicin—bone cancer	0.000186	0.00261	CcSEcCtD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000185	0.00117	CbGpPWpGaD
Rifabutin—Gastrointestinal pain—Methotrexate—bone cancer	0.000184	0.00259	CcSEcCtD
Rifabutin—HSP90AA1—Developmental Biology—MET—bone cancer	0.000184	0.00116	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—CDK4—bone cancer	0.000184	0.00116	CbGpPWpGaD
Rifabutin—Decreased appetite—Epirubicin—bone cancer	0.000183	0.00258	CcSEcCtD
Rifabutin—Gastrointestinal disorder—Epirubicin—bone cancer	0.000182	0.00256	CcSEcCtD
Rifabutin—Pain—Epirubicin—bone cancer	0.00018	0.00254	CcSEcCtD
Rifabutin—HSP90B1—Immune System—MDM2—bone cancer	0.00018	0.00113	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—ENO2—bone cancer	0.000179	0.00113	CbGpPWpGaD
Rifabutin—Body temperature increased—Methotrexate—bone cancer	0.000178	0.00251	CcSEcCtD
Rifabutin—Abdominal pain—Methotrexate—bone cancer	0.000178	0.00251	CcSEcCtD
Rifabutin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000178	0.0025	CcSEcCtD
Rifabutin—Insomnia—Doxorubicin—bone cancer	0.000177	0.00248	CcSEcCtD
Rifabutin—Paraesthesia—Doxorubicin—bone cancer	0.000175	0.00247	CcSEcCtD
Rifabutin—Dyspnoea—Doxorubicin—bone cancer	0.000174	0.00245	CcSEcCtD
Rifabutin—Feeling abnormal—Epirubicin—bone cancer	0.000174	0.00245	CcSEcCtD
Rifabutin—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000173	0.00109	CbGpPWpGaD
Rifabutin—Gastrointestinal pain—Epirubicin—bone cancer	0.000173	0.00243	CcSEcCtD
Rifabutin—Dyspepsia—Doxorubicin—bone cancer	0.000172	0.00242	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle—CDK4—bone cancer	0.00017	0.00107	CbGpPWpGaD
Rifabutin—Decreased appetite—Doxorubicin—bone cancer	0.00017	0.00239	CcSEcCtD
Rifabutin—HSP90AA1—Signaling Pathways—GRM1—bone cancer	0.000169	0.00107	CbGpPWpGaD
Rifabutin—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000169	0.00237	CcSEcCtD
Rifabutin—Pain—Doxorubicin—bone cancer	0.000167	0.00235	CcSEcCtD
Rifabutin—Body temperature increased—Epirubicin—bone cancer	0.000167	0.00235	CcSEcCtD
Rifabutin—Abdominal pain—Epirubicin—bone cancer	0.000167	0.00235	CcSEcCtD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000167	0.00105	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—DHFR—bone cancer	0.000166	0.00105	CbGpPWpGaD
Rifabutin—Hypersensitivity—Methotrexate—bone cancer	0.000166	0.00234	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle, Mitotic—RB1—bone cancer	0.000166	0.00104	CbGpPWpGaD
Rifabutin—Asthenia—Methotrexate—bone cancer	0.000162	0.00228	CcSEcCtD
Rifabutin—HSP90AA1—Axon guidance—MMP9—bone cancer	0.000162	0.00102	CbGpPWpGaD
Rifabutin—Feeling abnormal—Doxorubicin—bone cancer	0.000161	0.00226	CcSEcCtD
Rifabutin—Gastrointestinal pain—Doxorubicin—bone cancer	0.00016	0.00225	CcSEcCtD
Rifabutin—Pruritus—Methotrexate—bone cancer	0.00016	0.00224	CcSEcCtD
Rifabutin—HSP90AA1—Immune System—ATF1—bone cancer	0.000157	0.000987	CbGpPWpGaD
Rifabutin—HSP90B1—Immune System—JUN—bone cancer	0.000156	0.000985	CbGpPWpGaD
Rifabutin—Hypersensitivity—Epirubicin—bone cancer	0.000155	0.00219	CcSEcCtD
Rifabutin—Abdominal pain—Doxorubicin—bone cancer	0.000154	0.00217	CcSEcCtD
Rifabutin—Body temperature increased—Doxorubicin—bone cancer	0.000154	0.00217	CcSEcCtD
Rifabutin—Diarrhoea—Methotrexate—bone cancer	0.000154	0.00217	CcSEcCtD
Rifabutin—HSP90AA1—Developmental Biology—MMP2—bone cancer	0.000154	0.000968	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—KIT—bone cancer	0.000153	0.000965	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—IL3—bone cancer	0.000153	0.000963	CbGpPWpGaD
Rifabutin—Asthenia—Epirubicin—bone cancer	0.000151	0.00213	CcSEcCtD
Rifabutin—HSP90AA1—Metabolism—ENO2—bone cancer	0.00015	0.000947	CbGpPWpGaD
Rifabutin—Pruritus—Epirubicin—bone cancer	0.000149	0.0021	CcSEcCtD
Rifabutin—HSP90AA1—Cell Cycle—RB1—bone cancer	0.000148	0.000934	CbGpPWpGaD
Rifabutin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000148	0.000933	CbGpPWpGaD
Rifabutin—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000145	0.000915	CbGpPWpGaD
Rifabutin—Diarrhoea—Epirubicin—bone cancer	0.000144	0.00203	CcSEcCtD
Rifabutin—Hypersensitivity—Doxorubicin—bone cancer	0.000144	0.00202	CcSEcCtD
Rifabutin—Vomiting—Methotrexate—bone cancer	0.000143	0.00202	CcSEcCtD
Rifabutin—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000143	0.000903	CbGpPWpGaD
Rifabutin—Rash—Methotrexate—bone cancer	0.000142	0.002	CcSEcCtD
Rifabutin—Dermatitis—Methotrexate—bone cancer	0.000142	0.002	CcSEcCtD
Rifabutin—Headache—Methotrexate—bone cancer	0.000141	0.00199	CcSEcCtD
Rifabutin—Asthenia—Doxorubicin—bone cancer	0.00014	0.00197	CcSEcCtD
Rifabutin—HSP90AA1—Metabolism—DHFR—bone cancer	0.000139	0.000878	CbGpPWpGaD
Rifabutin—Pruritus—Doxorubicin—bone cancer	0.000138	0.00194	CcSEcCtD
Rifabutin—Vomiting—Epirubicin—bone cancer	0.000134	0.00189	CcSEcCtD
Rifabutin—Nausea—Methotrexate—bone cancer	0.000134	0.00188	CcSEcCtD
Rifabutin—Diarrhoea—Doxorubicin—bone cancer	0.000134	0.00188	CcSEcCtD
Rifabutin—Rash—Epirubicin—bone cancer	0.000133	0.00187	CcSEcCtD
Rifabutin—Dermatitis—Epirubicin—bone cancer	0.000133	0.00187	CcSEcCtD
Rifabutin—Headache—Epirubicin—bone cancer	0.000132	0.00186	CcSEcCtD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000131	0.000826	CbGpPWpGaD
Rifabutin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000131	0.000826	CbGpPWpGaD
Rifabutin—HSP90AA1—Axon guidance—EGFR—bone cancer	0.000131	0.000824	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—GNA11—bone cancer	0.00013	0.000821	CbGpPWpGaD
Rifabutin—HSP90AA1—Cellular responses to stress—TP53—bone cancer	0.000129	0.000815	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—MDM2—bone cancer	0.000126	0.000796	CbGpPWpGaD
Rifabutin—Nausea—Epirubicin—bone cancer	0.000125	0.00176	CcSEcCtD
Rifabutin—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000124	0.000783	CbGpPWpGaD
Rifabutin—Vomiting—Doxorubicin—bone cancer	0.000124	0.00175	CcSEcCtD
Rifabutin—Rash—Doxorubicin—bone cancer	0.000123	0.00173	CcSEcCtD
Rifabutin—Dermatitis—Doxorubicin—bone cancer	0.000123	0.00173	CcSEcCtD
Rifabutin—HSP90B1—Immune System—EGFR—bone cancer	0.000123	0.000774	CbGpPWpGaD
Rifabutin—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000123	0.000772	CbGpPWpGaD
Rifabutin—Headache—Doxorubicin—bone cancer	0.000122	0.00172	CcSEcCtD
Rifabutin—HSP90AA1—Disease—TGFBR2—bone cancer	0.000121	0.00076	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—MDM2—bone cancer	0.000121	0.00076	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—SMO—bone cancer	0.000119	0.000751	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—CYP3A4—bone cancer	0.000118	0.000744	CbGpPWpGaD
Rifabutin—Nausea—Doxorubicin—bone cancer	0.000116	0.00163	CcSEcCtD
Rifabutin—HSP90AA1—Developmental Biology—MMP9—bone cancer	0.000115	0.000727	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—GNA11—bone cancer	0.000109	0.000686	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—JUN—bone cancer	0.000105	0.00066	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—ATF1—bone cancer	0.000101	0.000638	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—GSTP1—bone cancer	0.000101	0.000637	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—IL3—bone cancer	9.87e-05	0.000622	CbGpPWpGaD
Rifabutin—CYP3A4—Biological oxidations—GSTP1—bone cancer	9.59e-05	0.000604	CbGpPWpGaD
Rifabutin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	9.46e-05	0.000596	CbGpPWpGaD
Rifabutin—HSP90AA1—Developmental Biology—EGFR—bone cancer	9.33e-05	0.000588	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—KIT—bone cancer	8.91e-05	0.000562	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—NDUFA12—bone cancer	8.71e-05	0.000549	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—TGFBR2—bone cancer	8.45e-05	0.000532	CbGpPWpGaD
Rifabutin—HSP90AA1—Innate Immune System—EGFR—bone cancer	8.24e-05	0.000519	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—KIT—bone cancer	8.23e-05	0.000519	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—IGF1R—bone cancer	7.95e-05	0.000501	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—BRAF—bone cancer	7.74e-05	0.000488	CbGpPWpGaD
Rifabutin—HSP90AA1—Cell Cycle—TP53—bone cancer	7.25e-05	0.000457	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—NT5C3A—bone cancer	7.21e-05	0.000455	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—MDM2—bone cancer	7.02e-05	0.000442	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—NDUFA12—bone cancer	6.72e-05	0.000423	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—MDM2—bone cancer	6.48e-05	0.000408	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—PTGS2—bone cancer	6.25e-05	0.000394	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—JUN—bone cancer	6.1e-05	0.000385	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—KIT—bone cancer	5.76e-05	0.000363	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—NT5C3A—bone cancer	5.57e-05	0.000351	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—BRAF—bone cancer	5.42e-05	0.000341	CbGpPWpGaD
Rifabutin—HSP90AA1—Metabolism—PTGS2—bone cancer	5.23e-05	0.00033	CbGpPWpGaD
Rifabutin—HSP90AA1—Immune System—EGFR—bone cancer	4.8e-05	0.000302	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—MDM2—bone cancer	4.54e-05	0.000286	CbGpPWpGaD
Rifabutin—HSP90AA1—Disease—EGFR—bone cancer	4.43e-05	0.000279	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—JUN—bone cancer	3.94e-05	0.000249	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—MMP9—bone cancer	3.84e-05	0.000242	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—ENO2—bone cancer	3.16e-05	0.000199	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—EGFR—bone cancer	3.1e-05	0.000195	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—DHFR—bone cancer	2.93e-05	0.000185	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—GNA11—bone cancer	2.74e-05	0.000173	CbGpPWpGaD
Rifabutin—HSP90AA1—Signaling Pathways—TP53—bone cancer	2.6e-05	0.000164	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—CYP3A4—bone cancer	2.48e-05	0.000157	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.47e-05	0.000156	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—ENO2—bone cancer	2.44e-05	0.000154	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—DHFR—bone cancer	2.26e-05	0.000143	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—GSTP1—bone cancer	2.12e-05	0.000134	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—GNA11—bone cancer	2.11e-05	0.000133	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—GSTP1—bone cancer	1.64e-05	0.000103	CbGpPWpGaD
Rifabutin—CYP1A2—Metabolism—PTGS2—bone cancer	1.1e-05	6.94e-05	CbGpPWpGaD
Rifabutin—CYP3A4—Metabolism—PTGS2—bone cancer	8.49e-06	5.35e-05	CbGpPWpGaD
